Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 2/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PKLR | P30613 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3136613 | 0.93 | ITGB2 (0.39) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL372145 | 0.93 | ITGB2 (0.39) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL20351197 | 0.91 | ITGB2 (0.38) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL3133241 | 0.91 | ITGB2 (0.38) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL13243539 | 0.91 | ITGB2 (0.38) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL3136653 | 0.89 | ABCG2 (0.46) | ITGB2ICAM1ITGALDRD1CYP3A4 | |
| SCHEMBL4837678 | 0.86 | DRD1 (0.38) | ITGB2ICAM1ITGALDRD1CYP3A4 | |
| SCHEMBL19928557 | 0.85 | DRD1 (0.36) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL9913796 | 0.85 | DRD1 (0.36) | ITGB2ICAM1ITGALSMN1; SMN2LMNA | |
| SCHEMBL18979231 | 0.84 | DRD1 (0.35) | ITGB2ICAM1ITGALSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032664-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | BUTLER DONALD E | 2007-02-08 | — | — | US | claimed |
| US-20050239869-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1eta-pyrrole-3-carboxylic acid phenylamide | BUTLER DONALD E | 2005-10-27 | — | — | US | claimed |
| US-20030195353-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo- tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | BUTLER DONALD EUGENE (US) | 2003-10-16 | — | — | US | claimed |
| US-6476235-B2 | CHEMICAL INTERMEDIATE; ANTICHOLESTEROL AGENTS, ANTILIPEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-11-05 | — | — | US | claimed |
| US-20020133026-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF 5-(4-FLUOROPHENYL)-1-[2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-PYRAN-2-YL)-ETHYL]-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE | BUTLER DONALD EUGENE (US) | 2002-09-19 | — | — | US | claimed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3272738-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2398774-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20100130745-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ETHENYLPHENYL ALCOHOLS | MCGARRITY JOHN | 2010-05-27 | — | — | US | disclosed |
| EP-1951695-B1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1988079-A1 | Process for the preparation of optically active ethenylphenyl-alcohols | LONZA AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008077560-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-AMINO-1-PHENYLETHANOLS | LONZA AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007061600-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | ITGB2 3626/4885ICAM1 4494/4885ITGAL 3423/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | ITGB2 4133/4885ICAM1 3193/4885ITGAL 3858/4885 |
| US-20100130745-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ETHENYLPHENYL ALCOHOLS | ADH1A, ADH1C, ADH5 | ITGB2 1195/4885ICAM1 2406/4885ITGAL 1135/4885 |
| US-20050239869-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1eta-pyrrole-3-carboxylic acid phenylamide | PAH, PCCA, HPD | ITGB2 4058/4885ICAM1 4758/4885ITGAL 4060/4885 |
| US-20030195353-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo- tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | PCCA, PAH, HPD | ITGB2 4226/4885ICAM1 4834/4885ITGAL 4050/4885 |
| US-20020133026-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF 5-(4-FLUOROPHENYL)-1-[2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-PYRAN-2-YL)-ETHYL]-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE | PCCA, PAH, HPD | ITGB2 4246/4885ICAM1 4812/4885ITGAL 4063/4885 |
| US-20070032664-A1 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide | PAH, PCCA, HPD | ITGB2 4171/4885ICAM1 4793/4885ITGAL 4041/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | ITGB2 4512/4885ICAM1 4035/4885ITGAL 3796/4885 |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | SRD5A1, HSD11B1, HSD3B1 | ITGB2 3507/4885ICAM1 4674/4885ITGAL 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.